PFS is improved with use of a TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy. Please summarize clinical results and implications for NGS testing.

PFS is improved with use of a TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy. Please summarize clinical results and implications for NGS testing.

PFS is improved with use of a TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy. Please summarize clinical results and implications for NGS testing.


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Jinming Yu, MD, PhD

Professor Jinming Yu, MD, PhD

President, Shandong Cancer Hospital and Institute
Jinan, Shandong
China